AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
Pfizer
This competitive program seeks proposals that improve safe, timely access to adequate antiviral COVID-19 treatment for eligible patients. Projects should leverage artificial intelligence (AI) and / or advanced clinical decision support to (1) identify patient eligibility based on current guidelines and clinical data and (2) proactively manage clinically significant drug–drug interactions (DDIs) to support appropriate disease management.
Individual projects requesting up to $500,000 USD will be considered. Maximum project length is 2 years.
Deadlines
| UM Internal Deadline (to ADR) | Sponsor Deadline | |
|---|---|---|
Application | 16-Jun-2026 | 07-Jul-2026 11:59 pm EST |
Important
The information in this directory is provided as a service to the University Community and anyone with legitimate business with the University. Use of this directory to prepare mass mailings is prohibited.